Dr. Stephen Salloway on the Implications of FDA's Decision on Aducanumab

Memory and Aging Home  

Clinical Trials  Prevention Registry  News & Events  Volunteer

 

News from the Memory and Aging Program at Butler Hospital

May, 2021

 

A decision from the FDA on whether to approve aducanumab as the first new treatment for Alzheimer's in the last 17 years is expected next month. What will it mean for the millions with early-stage disease if it is approved?

Dr. Stephen Salloway, director of the Memory and Aging Program and of Neurology at Butler Hospital and Professor of Psychiatry and Human Behavior and of Neurology at The Warren Alpert Medical School of Brown University, recently talked through the possibilities with Being Patient Alzheimer's

 

To learn more about the Memory and Aging Program and enrolling research studies focused on Alzheimer’s prevention and treatment, visit www.butler.org/memory or join Butler’s Prevention registry at butler.org/AlzRegistry to see if you qualify for any enrolling studies.

 

 

Explore More from The Memory and Aging Program at Butler Hospital

 


Subscribe to Our Memory Matters Newsletter

Get the latest research news, local stories and resources delivered straight to your inbox each month. 

Subscribe Now